【HER2 inhibitors】Trastuzumab(Herceptin®), Pertuzumab, Lapatinib, Antibody-drug conjugates (KADCYLA®)

Role of T-DM1 in HER2-Positive Metastatic Breast CancerПодробнее

Understanding and Treating HER2+ Breast CancerПодробнее

Adding lapatinib to adjuvant trastuzumab doesn't improve outcomes in HER2-positive breast cancerПодробнее

Anti-HER2 Mechanisms of Approved HER2 InhibitorsПодробнее

T-DM1 improves overall survival in previously treated advanced cancer patientsПодробнее

Trastuzumab Deruxtecan for Breast Cancer | NEJMПодробнее

Current Treatment Options for Patients With HER2-Positive Metastatic Breast CancerПодробнее

Get ALL the info you need about HER2 +ve BREAST CANCER - HER2 +ve BREAST CANCER || Dr Liz O'RiordanПодробнее

Welcome Session | 2021-2022 EMBRACE MBC Virtual Forum SeriesПодробнее

What is targeted therapy for breast cancer ? |Health QuestionsПодробнее

Capecitabine Plus Either Neratinib or Lapatinib for Patients With HER2 Breast CancerПодробнее

Kimberly L. Blackwell: Primary results from EMILIAПодробнее

HER-2 conversion: a phenomenon in trastuzumab resistanceПодробнее

The best sequence of anti-HER2 therapy in metastatic breast cancerПодробнее

ASCO: New Treatment (T-DM1) for HER2-Positive Advanced Breast Cancer?Подробнее

Dr. Debu Tripathy Discusses the Updated EMILIA Trial Results for T-DM1Подробнее